Free Gastroenterology CME

  • FREE

    ScientiaCME Gastroenterology

    This course contains two courses:

    Target Audience:

    Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release.
  • FREE

    ScientiaCME Treating advanced-stage gastric and gastroesophageal junction cancers: updates from ASCO 2023

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Staging of GC & GEJC depends on the tumor’s histopathology, location, and degree of spread, and 36% of patients in the U.S. are diagnosed in the advanced stages of the disease because the signs and symptoms are often initially clinically silent for most of the disease course, and missed opportunities for identification are not uncommon. The prognosis of GC & GEJC is poor: the 5-year overall survival (OS) rate of GC is 32%, with the five-year OS rate of patients with advanced disease is six percent.

    Target Audience:
    HCPs including: Medical oncologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 27, 2023
    • Expiration of CME credit: July 27, 2024
  • FREE

    ScientiaCME Acute hepatic porphyria: optimizing pharmacotherapeutic management strategies

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Acute hepatic porphyria (AHP) is an umbrella term for four types of acute porphyria, the most severe of which is acute intermittent porphyria (AIP). An estimated 80% of AHP cases are AIP, which is an inherited autosomal dominant condition that results from mutations of the third enzyme of heme synthesis, porphobilinogen deaminase. In the Western countries, it is estimated that approximately 1 in 2000 individuals are carriers of the relevant mutated genotype, although the majority have latent AIP and are clinically asymptomatic. Acute attacks occur in less than 10% of the at-risk population, reflecting the role of environmental factors, such as alcohol use, infections, and hormonal changes, among others. AHP symptoms are believed to be caused by ALAS1-mediated accumulation of ALA and PBG in the liver and bloodstream, leading to neurotoxicity.

    Target Audience:
    The following HCPs: hematologists and gastroenterologists; physician assistants, nurse practitioners, and pharmacists who practice in any of the aforementioned areas of specialties; and any other healthcare professionals with an interest in or who clinically encounter patients with AHP.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 06, 2023
    • Expiration of CME credit: July 06, 2025
  • FREE

    The difficulty with (C.) difficile: guideline updates and optimal identification and treatment strategies

    Activity Description / Statement of Need:

    Clostridioides difficile (formerly known as Clostridium difficile) is a gram-positive obligate anaerobe that produces exotoxins in the gastrointestinal (GI) tract resulting in watery, loose stool, abdominal pain, and nausea. The U.S. incidence of Clostridioides difficile infection (CDI) is about half a million people, with 28% community-acquired, 37% healthcare-associated, and 36% associated with long-term care facilities. Additionally, CDI has incurred one billion dollars in costs to the U.S. healthcare system. Antibiotic exposure causes changes to the GI microflora and increases the risk of developing CDI, which is especially seen in carbapenems, third-/fourth- generation cephalosporins, clindamycin, and fluoroquinolone use. Other risk factors include acid suppressive therapy; age; prolonged hospitalizations or other recent healthcare exposure; recent tube feeding or GI surgery; and immunocompromised states, including recent chemotherapy.

    Target Audience:

    HCPs including: infectious diseases physicians, gastroenterologists, hospitalists, and intensivists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CDI. 

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 02/04/2022
    • Expiration of CME credit: 02/04/2024
  • FREE

    Advances in the diagnosis and management of non-alcoholic steatohepatitis (NASH): best practices and emerging therapies

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, with the accumulation of fat in the liver in excess of five percent of the liver’s weight, together with hepatic inflammation in the presence or absence of fibrosis. Risk factors for NASH include a number of comorbid metabolic diseases and disorders, including metabolic syndrome, obesity, type 2 diabetes, hypertension, and dyslipidemia. The prevalence of NASH is estimated to be 1.5%-6.45% of the U.S. population, and prevalence of NASH among NAFLD patients to be 59.1% globally.

    Target Audience:

    The following HCPs in: Gastroenterology, hepatology, and endocrinology; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with NAFLD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/07/2022
    • Expiration of CME credit: 06/07/2024
  • FREE

    Novel and emerging therapies for constipation-predominant irritable bowel syndrome (IBS-C) and Chronic Idiopathic Constipation (CIC)

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. While the precise pathophysiology is still an area of active investigation, it appears to include a neuro-enteric disconnect, leading to intestinal somato-visceral and motor dysfunction. Genetic, immune function, microbiome, psychological, and environmental factors may also predispose patients to develop of IBS. Its prevalence varies according to country and the criteria used to define it. In North America and Europe, it has a 10-15% prevalence, and it varies by country. In the U.S. and Canada, IBS symptoms are 1.5 to 2 times more prevalent among women. Women commonly report abdominal pain and constipation while men report diarrhea. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life. 

    Target Audience:

    The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology and internal medicine; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/26/2022
    • Expiration of CME credit: 06/26/2024
  • FREE

    Initial and later line approaches to the systemic treatment of unresectable and metastatic gastric and gastroesophageal junction (GEJ) cancer

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Staging of GC & GEJC depends on the tumor’s histopathology, location, and degree of spread, and 36% of patients in the U.S. are diagnosed in the advanced stages of the disease because the signs and symptoms are often initially clinically silent for most of the disease course, and missed opportunities for identification are not uncommon. The prognosis of GC & GEJC is poor: the 5-year overall survival (OS) rate of GC is 32%, with the five-year OS rate of patients with advanced disease is six percent.

    Target Audience:

    HCPs including: Medical oncologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 02/01/2023
    • Expiration of CME credit: 02/01/2024